Zydus Gets Phase III Trial Approval; Shares Rise 2.35%

Mumbai, April 27: Zydus Lifesciences Limited said it has received approval from the Drugs Controller General of India to begin Phase III clinical trials for its anti-malarial drug candidate, Zintrodiazine.

Phase III trials are the final stage of testing before a drug can be considered for approval. They typically involve larger patient groups to confirm safety and effectiveness across broader populations, according to an exchange filing dated April 25, 2026.

The company said the trials will be conducted at multiple centres across India and will include two parallel studies. One study will enrol 651 patients with uncomplicated malaria caused by Plasmodium falciparum, while the other will involve 390 patients with Plasmodium vivax infections.

In addition to measuring treatment outcomes, the studies will track recurrence rates, parasite clearance and the time taken for fever to subside—factors that are important in assessing how a drug performs in real-world conditions.

Stock Edges Higher As Pipeline Progress Gains Visibility

Zydus Lifesciences  share price moved higher after the update, indicating a positive but measured response from investors.

As of 12:29 IST on April 27, 2026, the stock was trading at ₹949.15, up ₹21.75 or 2.35% from the previous close of ₹927.40, according to exchange data.

The gains were steady through the session, suggesting investor interest tied to longer-term potential rather than immediate impact.

Tackling Resistance In Malaria Treatment

The development comes as concerns grow over resistance to existing malaria treatments.

Zintrodiazine is being developed to target both major malaria-causing parasites, including strains that have shown reduced response to current therapies. Resistance to artemisinin-based treatments, widely used as first-line therapy, has been reported in several regions.

The company said the programme is part of its broader effort to address these challenges and expand treatment options.

Company Background And Research Orientation

Zydus Lifesciences operates across generics, vaccines, biologics and new drug development.

The company has invested in research and development over the years, building capabilities to support both large-scale manufacturing and innovation-driven programmes. Its pipeline includes products aimed at addressing unmet medical needs.

Conclusion

The approval to start Phase III trials for Zintrodiazine marks an important step in its development, though further testing and regulatory review remain.

The rise in the Zydus Lifesciences share price reflects cautious optimism, with investors likely to track progress in the trials and future updates on the programme.

Source:

• https://www.nseindia.com/get-quote/equity/ZYDUSLIFE/Zydus-Lifesciences-Limited
• https://nsearchives.nseindia.com/corporate/Cadilahc_25042026124649_PressRelease25042026.pdf